

Listeria monocytogenes Promotes Tumor Growth via Tumor Cell Toll-Like Receptor 2 Signaling

Bo Huang,¹ Jie Zhao,² Shiqian Shen,³ Hongxing Li,⁴ Kai-Li He,⁵ Guan-Xin Shen,³ Lloyd Mayer,⁴ Jay Unkeless,⁴ Dong Li,¹ Ye Yuan,¹ Gui-Mei Zhang,¹ Huabao Xiong,⁴ and Zuo-Hua Feng¹

Departments of ¹Biochemistry and Molecular Biology, ²Gynecology and Obstetrics, and ³Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, The People's Republic of China; ⁴Immunobiology Center, Mount Sinai School of Medicine; and ⁵Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, New York

Abstract

The contribution of bacterial infection to tumorigenesis is usually ascribed to infection-associated inflammation. An alternate view is that direct interaction of bacteria with tumor cells promotes tumor progression. Here, we show that the microenvironment of large tumors favors bacterial survival, which in turn directly accelerates tumor growth by activating tumor cell Toll-like receptors (TLR). *Listeria monocytogenes* (*Lm*) survives in the microenvironment of large but not small tumors, resulting in the promotion of tumor growth. *Lm* did not affect the percentage of regulatory T cells or myeloid suppressor cells in the tumor. Through TLR2 signaling, *Lm* activated mitogen-activated protein kinases and nuclear factor- κ B in tumor cells, resulting in the increased production of nitric oxide and interleukin-6 and increased proliferation of tumor cells. All of these effects were abrogated by silencing expression of TLR2, but not TLR4. The interaction of *Helicobacter pylori* with tumor cells from gastric carcinoma patients resulted in similar effects. These findings provide a new insight into infection-associated tumorigenesis and illustrate the importance of antibiotic therapy to treat tumors with bacterial infiltration. [Cancer Res 2007;67(9):4346–52]

Introduction

Chronic infection by bacteria is recognized as a risk factor for tumorigenesis, and the underlying mechanism is ascribed to infection-induced inflammation (1–3). The inflammatory response is triggered by interaction between bacteria and Toll-like receptors (TLR) expressed on immune cells or local tissue (4, 5). Chronic inflammation promotes neoplastic cell growth, may contribute to neovascularization (6), and is proposed as an initiating factor in ~15% of human tumors (7). Nevertheless, the use of bacterial vaccines for immunotherapy of tumors is being reexamined because bacterial vaccines might efficiently activate a durable and robust antitumor response (8, 9). In particular, *Listeria monocytogenes* (*Lm*), a Gram-positive facultative intracellular bacterium, is being developed as a cancer vaccine platform because it can induce a potent innate and adaptive response (10–12). Furthermore, virulence-attenuated strains of *Lm* have

been confirmed to have the same antitumor capacity as wild-type (WT) *Lm* (13), which may lead to clinical trials in the future.

Although much attention in recent years has been paid to the interaction between host and pathogen, direct interaction between bacteria and tumor cells has been largely overlooked. It is still unclear how tumor-associated bacteria interact with tumor cells and how the consequences of such interactions influence tumor progression and immunotherapy. Given that the tumor-associated bacteria can come not only from infection but also from immunization with bacterial vaccines, it is important to study the effects of interaction between bacteria and tumor cells on the tumor. We previously reported that tumor cells express TLRs (14) and suggested a potential link between tumor-associated bacteria and tumor cells. In this study, we found that the direct injection of *Lm* into local tumors resulted in the promotion of tumor growth rather than inhibition. This effect was due to the activation of tumor cell TLR signaling by *Lm*. These findings emphasize that the presence of bacteria in the tumor can directly accelerate tumor growth and suggest that antibiotic therapy may be beneficial to the treatment of bacterial infection-associated cancer.

Materials and Methods

Mice and cell lines. BALB/c (H-2^d) mice were purchased from the National Cancer Institute. The WT hepatocarcinoma H22 cell line (BALB/c background) and TLR2 and TLR4 knockdown H22 cell lines were grown in DMEM supplemented with 10% fetal bovine serum (FBS) and 4 mmol/L glutamine.

Preparation of *Lm* bacteria. *Lm* 104035, a virulent strain (a gift from Dr. Hao Shen, University of Pennsylvania, Philadelphia, PA; ref. 15), was used throughout the study. The bacteria were grown in Brain Heart Infusion Broth (BD Biosciences) at 37°C for 16 h, washed repeatedly, suspended in PBS, and stored at –80°C until use.

Tumor growth experiment. H22 tumor cells (2×10^5) were inoculated s.c. to the left flank of BALB/c mice ($n = 10$ per group). Tumor growth was monitored every 5 days by palpation. The length (L) and width (W) of tumors were measured, and the volume of tumor (V) was determined by the following formula: $V = (L \times W^2) / 2$.

In vivo depletion of natural killer cells or immunoregulatory cells. Natural killer (NK) cell *in vivo* depletion was referenced previous method (16) by i.p. injection of 50 μ L of rabbit polyclonal antibody against asialo ganglio-N-tetraosylceramide (AGM1; Wako Chemicals). CD4⁺CD25⁺ regulatory T cell (Treg) was depleted *in vivo* by i.p. injection of 100 μ L of anti-mouse CD25 antibody (PC61.5; eBioscience). Myeloid suppressor cells (MSC) were depleted *in vivo* by i.p. injection of 100 μ L of anti-mouse Gr-1 antibody (RB6-8C5; eBioscience).

Cytotoxicity assay. Tumor cells (5×10^6) were infected by incubation with *Lm* [1×10^8 colony-forming unit (CFU)] for 2 h and then cultured with 5 μ g/mL gentamicin (17). Two days later, a fraction of cells were lysed and inoculated on agar plate for *Lm* culture. The white colonies were counted for the identification of infection of tumor cells by *Lm*. The infected tumor cells, colonies/cells >1, were used as target cells for cytotoxicity assay.

Requests for reprints: Zuo-Hua Feng, Department of Biochemistry and Molecular Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, The People's Republic of China. Phone: 86-27-83650754; Fax: 86-27-83650754; E-mail: fengzhg@public.wh.hb.cn or Huabao Xiong, Immunobiology Center, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6574. Phone: 212-659-9413; Fax: 212-849-2525; E-mail: Huabao.Xiong@mssm.edu.

©2007 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-06-4067

Mice received 2×10^3 CFU of live *Lm* by i.v. injection followed by the second i.v. injection of 4×10^4 CFU of live *Lm* 7 days later. The splenic T cells were isolated with T-cell enrichment column (R&D Systems) from control mice or *Lm*-vaccinated mice 7 days after the second injection with *Lm* and used as effector cells.

Standard 4-h ^{51}Cr release assay was done. Briefly, target cells were labeled with $\text{Na}^{51}\text{CrO}_4$ ($0.1 \mu\text{Ci}/10^6$ cells; Amersham Pharmacia Biotech) at 37°C for 1 h. After extensive washing, target cells were incubated with effectors at different E:T ratios in triplicate for 4 h at 37°C , and ^{51}Cr released (cpm) into the supernatants was measured in a gamma counter to calculate percentage specific release. The percentage specific lysis was calculated by the following formula: percentage lysis = $100 \times (\text{experimental release} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release})$.

Flow cytometry. H22 tumor cells (2×10^5) were inoculated s.c. to mice. On day 15, 1×10^6 CFU of live *Lm* were injected directly to tumor site. Ten days later, tumor tissues were removed and digested with collagenase and hyaluronidase and grinded to single cells. The leukocytes in tumor tissues were isolated using Lymphocyte Separation Medium (Cellgro). Both tumor-infiltrating leukocytes and the grinded splenocytes were stained with phycoerythrin-labeled anti-CD3, FITC-labeled anti-CD4, and allophycocyanin (APC)-labeled anti-CD25 for Treg analysis by flow cytometry. To analyze MSCs, single cells from tumor tissue or spleen were fractionated by centrifugation on a Percoll (Amersham Biosciences) density gradient as described (18). The cells in fraction 2 were stained with APC-labeled anti-Gr-1 and FITC-labeled anti-CD11b. All above antibodies and their isotype-matched monoclonal antibodies were purchased from eBioscience.

Isolation and culture of *Helicobacter pylori*. The gastric specimens from surgery were transported to the laboratory within 1 h. Three biopsy specimens from *Helicobacter pylori*-positive patients were homogenized and inoculated onto trypticase soy sheep blood agar medium (BD, Becton Dickinson Microbiology Systems) containing $10 \mu\text{g}/\text{mL}$ vancomycin, $5 \mu\text{g}/\text{mL}$ trimethoprim, and $2.5 \text{ IU}/\text{mL}$ polymyxin B and then incubated at 35°C in an atmosphere of 10% CO_2 and 95% relative humidity. The *H. pylori* were identified by Gram-stained smear and positive oxidase, catalase, and urease tests.

Isolation of tumor cells from gastric carcinoma patients. Human gastric cancer tissues were acquired from clinical operation and digested with collagenase and hyaluronidase for 1 h at 37°C . After grinding with semifrosted slides and lysis of RBC, the dissociated cells were incubated on ice for 20 min and then spun down at 500 rpm for 1 min. This process was repeated twice and the cells were first incubated for 2 h to get rid of adhesive cells. The gastric tumor cells were then cultured in DMEM supplemented with 10% FBS, 2 mmol/L L-glutamine, 1.0 mmol/L sodium pyruvate, 100 units/mL penicillin G sodium, and $100 \mu\text{g}/\text{mL}$ streptomycin sulfate in six-well plate in a humidified incubator at 37°C with 5% CO_2 . The low-passage cells (less than three passages) were used for *H. pylori* stimulation assay or cell transfection.

Tumor cell proliferation assay. H22 cells were seeded in 96-well plate (5×10^3 per well) and treated with heat-killed *Lm* (1×10^5 CFU) for 48 h. The proliferation assay was done with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation kit (Roche Diagnostics) according to the manufacturer's instructions. The proliferation of gastric carcinoma cells in the presence of *H. pylori* was determined by the same method with 5×10^3 of gastric carcinoma cells and 2×10^5 CFU of *H. pylori* per well. Before the addition of MTT, cells were washed with warm culture medium by spinning the plate at 500 rpm for 1 min and then discarding the supernatant. This washing procedure was repeated thrice to avoid the possible influence of *H. pylori*.

Quantification of *Lm* in tissues. *Lm*-vaccinated mice were sacrificed. The spleen and tumor tissue from the mice were homogenized in 5 mL of sterile PBS. Homogenates ($100 \mu\text{L}$) were added to sterile Brain Heart Infusion Agar plate and incubated at 37°C for 18 h. The white colonies were counted.

Western blot. Cell lysates ($30 \mu\text{g}$ of total protein) and prestained molecular weight markers were separated by SDS-PAGE followed by transfer onto nitrocellulose membranes. The membranes were blocked in TBS with 0.5% of Triton X-100 containing 5% nonfat milk and probed with various antibodies (1:1,000). After incubation with the secondary antibody

conjugated with horseradish peroxidase, membranes were extensively washed, and the immunoreactivity was visualized by enhanced chemiluminescence (ECL) according to the manufacturer's protocol (ECL kit, Santa Cruz Biotechnology). All antibodies were purchased from Cell Signaling.

Cell transfection and luciferase assay. Nuclear factor- κB (NF- κB) activity in cells was detected with a NF- κB -luciferase reporter vector (pSV40 κB -luc). The NF- κB -binding sites in the vector consist of four concatemers of the synthetic oligonucleotide 5'-CTAGTGGGGACTTTC-CACCTGGGGACTTTCACCT-3', each of which contains two NF- κB -binding sites derived from SV40 virus. The sequence encoding for firefly luciferase is controlled by eight NF- κB -binding sites and a synthetic basal TATA element. H22 cells (1×10^6) were transiently transfected with pSV40 κB -luc (stored at laboratory) with LipofectAMINE Plus reagents (Invitrogen) in six-well plates. To normalize experiments for transfection efficiency, cells were cotransfected with a β -galactosidase reporter plasmid driven by cytomegalovirus promoter. The cells were harvested 24 h after transfection and extracted with reporter lysis buffer (Promega), and $20 \mu\text{L}$ of extract were used for the assay of luciferase activity as described (19). When indicated, heat-killed *Lm* was added to the culture for 6 to 12 h before harvest. The similar strategy was used for transfection of NF- κB -luciferase reporter plasmid to human gastric carcinoma cells.

Reverse transcription-PCR. Tumor cells were homogenized with Trizol reagent (Invitrogen), and total RNA was extracted according to the manufacturer's instructions. A reverse transcription-PCR (RT-PCR) procedure was used to determine relative quantities of mRNA (One-Step RT-PCR kit, Qiagen). Twenty-eight PCR cycles were used for all of the analyses, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control. The primers for all genes tested were described as follows: *GAPDH*, 5'-GTGGAGATTGTTGCCATCAACG-3' (sense) and 5'-CAGTGGATGCAGGGATGATGTTCTG-3' (antisense); *TLR2*, 5'-GTCTTTCACCTCTATTCCTC-3' (sense) and 5'-GTCTCTACATTCC-TATCTG-3' (antisense); *TLR4*, 5'-GAAACTCAGCAAAGTCCCTG-3' (sense) and 5'-GAAAGGCTTGGTCTGAATG-3' (antisense); *interleukin-6* (*IL-6*), 5'-GAGAGGAGACTTCACAGAGGATAC-3' (sense) and 5'-GTACTCCAG-AAGACCAGAGG-3' (antisense); *inducible nitric oxide synthase* (*iNOS*), 5'-GAGATTGGAGTTCGAGACTTCTGTG-3' (sense) and 5'-TGGCTAGTG-CTTCAGACTTC-3' (antisense).

Assay for NO production and cytokine release. NO production was measured using Greiss reagent (Sigma-Aldrich). Cytokine IL-6 in the supernatants of tumor cell culture was quantified by ELISA (R&D Systems).

Construction of H22 tumor cell lines expressing TLR2 and TLR4 siRNA. TLR2 sense and antisense small interfering RNAs (siRNA) were generated using Silencer siRNA construction kit according to the manufacturer's instruction (Ambion). After hybridization and purification, the different double-stranded TLR2 siRNAs and control siRNA were transiently transfected into H22 tumor cells using GeneSilencer siRNA transfection reagent (Gene Therapy Systems). The most efficient TLR2 siRNA sequence (gtccagcagaatacaat) and its control siRNA sequence (gtcacagatcacatacca) were verified by RT-PCR detection of TLR2 mRNA 24 h after transfection and inserted into RNAi-Ready pSIREN-RetroQ expressing vector with U6 promoter (BD Biosciences, Clontech). The TLR4 siRNA (gtcctgatgacattcct) and its control (gtctgactgacatttcc) siRNA-expressing vectors were constructed in the same way. The recombinant TLR2 and TLR4 siRNA-expressing plasmids and control plasmids were transfected into H22 tumor cell using FuGENE 6 transfection reagent (Roche) for stable expression after selection. Briefly, 48 h after transfection, puromycin was added to the medium to the final concentration of $15 \mu\text{g}/\text{mL}$ and the puromycin was replenished every 3 days. After 4-week selection, the clones were identified by RT-PCR.

Statistical analysis. Results were expressed as mean values \pm SE deviation, and the difference was determined by the Student's *t* test. A *P* value of <0.05 was considered significant.

Results

Effects of *Lm* on tumor growth. To analyze the interrelationship between *Lm* and tumor, we first examined the effects of *Lm*




Figure 1. Effects of *Lm* on tumor growth. *A*, *Lm* vaccination inhibited tumor growth by activating NK cells. The mice received 2×10^3 CFU of live *Lm* i.v. followed the next day by s.c. inoculation of H22 tumor cells. A second dose of 4×10^4 CFU of live *Lm* was given i.v. 7 d later. Controls were injected with PBS and inoculated with tumor cells as before. The anti-NK cell antibody was injected i.p. 1 d before each *Lm* vaccination. *B*, cytotoxicity of *Lm*-specific T cell to *Lm*-infected tumor cell. The cytotoxicity was determined *in vitro* as described in Materials and Methods. *C*, *Lm* promoted tumor growth. The experiment was done as in (*A*), except that 1×10^6 CFU of live *Lm* were injected directly to tumor mass of mice in one of two *Lm* vaccination groups on day 15 after inoculation of tumor cells.

vaccination on tumor growth. When mice were inoculated with H22 tumor cells after vaccination by i.v. injection with *Lm* and received second vaccination with a 20-fold higher i.v. dose of *Lm* 7 days later, the growth of tumor was significantly suppressed (Fig. 1A). Depletion of NK cells abrogated the antitumor effect of *Lm* vaccination (Fig. 1A), suggesting the importance of NK cells for this effect.

To explore the possibility of increasing the antitumor effect of *Lm* vaccination by *Lm*-specific cytotoxic T cells, we isolated *Lm*-specific T cells from *Lm*-vaccinated mice and determined their cytotoxicity toward *Lm*-infected tumor cells. The results of the cytotoxicity assay showed that splenocytes from *Lm*-vaccinated mice effectively killed *Lm*-infected H22 cells and macrophages but




Figure 2. Effects of *Lm* and depletion of suppressor cells on tumor growth. H22 tumor cells (2×10^5) were inoculated s.c. On day 14, either anti-CD25 or anti-Gr-1 antibody was administered i.p. thrice every 72 h. On day 15, 1×10^6 CFU of live *Lm* were directly injected into tumor mass. *A*, the depletion of either Treg or MSC suppressed the growth of tumor, but the injection of *Lm* promoted tumor growth. The experiments were done as described above and tumor volumes were measured. *B*, the Treg and MSC populations in spleen and tumor tissue of mice in control group, *Lm* injection group, and depletion group were analyzed by flow cytometry.

Downloaded from http://aacrjournals.org/cancerres/article-pdf/67/9/4346/2579539/4346.pdf by guest on 29 April 2025




Figure 3. The interrelationship between bacteria and tumor. *A*, bacteria directly promoted the growth of tumor cells *in vitro*. Mouse H22 hepatocarcinoma cells and human gastric cancer cells were cultured in the presence or absence of *Lm* or *H. pylori*, respectively, and the proliferation of cells was quantified as described in Materials and Methods. *, $P < 0.05$, Student's *t* test, significantly different from control. *B* and *C*, *Lm* survived in local tumor. Tumor cells (2×10^5) were inoculated s.c., and on day 15 (*B*) or day 3 (*C*) after tumor inoculation, 4×10^5 (high dose) or 4×10^4 (low dose) CFU of live *Lm* were injected i.v. On day 3 or day 10 after *Lm* injection, the bacteria in spleen and tumor tissue were quantified as described in Material and Methods. *D*, *Lm* promoted the growth of large tumor. Mice were inoculated with 2×10^5 H22 tumor cells, and 1×10^6 CFU of live *Lm* were injected directly into the tumor on days 3 and 15, respectively.

had minimal cytotoxicity to control H22 cells (Fig. 1*B*). To validate this *in vitro* result *in vivo*, we injected *Lm* into the tumor mass in *Lm*-vaccinated mice. However, the injection of *Lm* into the tumor promoted instead of inhibiting tumor growth (Fig. 1*C*).

The protumor effect of *Lm* is not due to cell-mediated immunosuppression. To explain the unexpected positive effect of *Lm* on tumor growth, we hypothesized that *Lm* injected into tumor enhanced the immune escape through cell-mediated immunosuppression. To test this, we investigated the effect of *Lm* in the presence or absence of Treg or MSC, the main immunosuppressive cell types in tumors (20–23). The injection of *Lm* promoted the growth of tumor (Fig. 2*A*), which, however, was not due to the effect of *Lm* on immunosuppressive cells. First, depletion of either Treg or MSC did not abrogate the effect of *Lm* on tumor growth (Fig. 2*A*). Second, 10 days after the injection of *Lm* into the tumor, the proportions of CD4⁺CD25⁺ Treg and Gr-1⁺CD11b⁺ MSC were unchanged in both tumor and spleen relative to those in control mice (Fig. 2*B*), indicating that *Lm* did not influence these immunoregulatory cells.

Bacteria interact directly with tumors *in vitro*. Based on the above data, we further hypothesized that *Lm* could directly promote the growth of tumor cells. To test this, H22 cells were cultured in the presence or absence of *Lm*. We found that the growth of tumor cells was accelerated by *Lm* (Fig. 3*A*), indicating that *Lm* could affect tumor cells by direct interaction. In agreement with these results, when gastric tumor cells from *H. pylori*-negative patients were cultured in the presence of live *H. pylori* isolated from *H. pylori*-positive gastric cancer patients, the growth of human gastric tumor cells was accelerated relative to controls

(Fig. 3*A*). Same stimulating effect was observed by using heat-killed *H. pylori* (data not shown).

Survival of bacteria in tumors. A prerequisite for the direct effect of bacteria on tumor proliferation is the presence of bacteria within the tumor for a relatively long period. To verify this, the mice with either large tumors or impalpable tumors were injected i.v. with either high or low doses of *Lm*. On day 3 after the injection of *Lm*, viable bacteria were quantified in spleens of each group and also in the large tumors. On day 10 after the injection, viable *Lm* was found only in tumor tissues receiving *Lm* injection 15 days after tumor inoculation (Fig. 3*B*), but not in those receiving *Lm* injection 3 days after tumor inoculation (Fig. 3*C*) nor in the spleen of either group, indicating that *Lm* could only survive for a longer period in large tumors. In agreement with these observations, when *Lm* was injected directly into tumor inoculation sites of unvaccinated mice, *Lm* only promoted the growth of large tumors that were 7×7 mm at the time of *Lm* injection but not that of tumors that were impalpable at the time of *Lm* injection (Fig. 3*D*), suggesting that the continuous existence of *Lm* in tumor is needed for its tumor-promoting effect.

Bacteria increase the activation of mitogen-activated protein kinases and NF- κ B in tumor cells. The increase in proliferation in the presence of bacteria suggests that the bacteria directly affect tumor cell signaling pathways. We therefore analyzed mitogen-activated protein kinases (MAPK) and NF- κ B pathways commonly activated by pathogens. In the presence of *Lm*, the activation of MAPKs extracellular signal-regulated kinase (ERK) and c-Jun NH₂-terminal kinase (JNK) in H22 cells was obviously increased (Fig. 4*A*). The activity of NF- κ B in H22 cells was also

significantly increased in the presence of heat-killed *Lm* (Fig. 4B), evaluated with a NF- κ B-luciferase reporter plasmid. The increased activity of NF- κ B on stimulation of H22 cells by *Lm* was further confirmed by the increased expression of mRNA and protein for the downstream target genes *iNOS* and *IL-6* (Fig. 4C). Comparable results were obtained following incubation of heat-killed *Lm* with B16 melanoma cells (data not shown). To generalize these results to human tumors, we tested the NF- κ B activity of gastric tumor cells after *H. pylori* stimulation. Tumor cells were isolated from *H. pylori*-negative gastric cancer patients, transfected with a NF- κ B-luciferase reporter plasmid, and cultured in the presence of *H. pylori* isolated from *H. pylori*-positive patients. NF- κ B activity was induced in the tumor cells by incubation with *H. pylori*, and the NF- κ B-regulated genes *iNOS* and *IL-6* were also strongly induced (Fig. 4D).

***Lm* triggers the signal transduction in tumor cells through TLR2.** Our previous study indicated that tumor cells express a variety of TLRs and that NF- κ B and MAPKs are the signal transducers in TLR signaling pathway. To test the hypothesis that TLR stimulation of tumor cells induces the cytokine secretion and proliferation we observed on incubation with bacteria, we constructed TLR2 and TLR4 knockdown H22 tumor cell lines (Fig. 5A). The TLR2 knockdown tumor cells, but not TLR4 knockdown tumor cells,

largely failed to respond to *Lm*, judged by the activation of NF- κ B and production of NO and IL-6 (Fig. 5B), indicating that TLR2, rather than TLR4, was important for *Lm* signaling.

To further elucidate the role of TLR2 in the tumor-promoting effect of *Lm*, we investigated the influence of *Lm* on proliferation and tumor growth in the presence or absence of TLR2 signaling. The stimulation with *Lm* significantly increased proliferation of both WT and TLR4 knockdown H22 tumor cells relative to that of cells without *Lm* stimulation but not that of TLR2 knockdown H22 cells (Fig. 5C). Finally, *Lm* was directly injected into large tumor formed by TLR2 knockdown H22 cells. In the absence of TLR2 signaling, *Lm* had no effect on tumor growth compared with that of the control group (Fig. 5D). Taken together, these data indicate that TLR2, but not TLR4, is required for *Lm*-triggered signal transduction of H22 tumor cells to promote tumor growth.

Discussion

It has been suggested that chronic bacterial infection may play a role in tumorigenesis and that the underlying mechanisms are connected with the infection-mediated inflammation (1–3). In this study, we provide new insight into the relationship between bacteria and tumorigenesis. The direct interaction of bacteria with




Figure 4. Bacteria increased the activation of MAPKs and NF- κ B in tumor cells. *A*, activation of MAPKs in H22 cells. H22 cells were stimulated with heat-killed *Lm* [multiplicity of infection (MOI) of 100] for intervals as shown, and the phosphorylation of ERK and JNK was analyzed by immunoblotting with phosphorylation-specific and control antibodies. *B*, activation of NF- κ B in H22 cells. H22 cells were transfected with a NF- κ B-luciferase reporter plasmid, and the cells were then incubated with *Lm*. After 24 h, extracts were assayed for luciferase as described. *C*, expression of *iNOS* and *IL-6* in H22 cells. H22 cells were stimulated with heat-killed *Lm* for 8 h for the analysis of mRNA expression by RT-PCR or for 48 h for the measurement of the production of NO and IL-6 by Greiss reagent and ELISA, respectively. *, $P < 0.05$, Student's *t* test, significantly different from control. *D*, *H. pylori* activated NF- κ B in gastric carcinoma cells. *Top*, activation of NF- κ B by *H. pylori* in gastric carcinoma cells. The tumor cells were isolated from *H. pylori*-negative gastric cancer patients, transfected with a NF- κ B-luciferase reporter plasmid, and cocultured with *H. pylori* at a MOI of 100. Luciferase was assayed as in (*B*). *, $P < 0.05$, Student's *t* test. *Middle* and *bottom*, expression of *iNOS* and *IL-6* in gastric carcinoma cells after *H. pylori* stimulation. The tumor cells were stimulated with *H. pylori* for 48 h for the measurement of the production of NO and IL-6 by Greiss reagent and ELISA, respectively. *, $P < 0.05$, Student's *t* test.




Figure 5. The effect of *Lm* on tumor growth was mediated by TLR2. *A*, silencing TLR2 and TLR4 with siRNA. After stable transfection of TLR2 siRNA or TLR4 siRNA vectors into H22 tumor cell line, TLR2 mRNA and TLR4 expression were examined by RT-PCR. *B*, TLR2, and not TLR4, is required for *Lm*-stimulated NF- κ B activation and the production of NO and IL-6 after *Lm* stimulation. Permanently expressing siRNA TLR2 and TLR4 H22 cell lines and control cells were transfected with a NF- κ B-luciferase reporter plasmid to analyze NF- κ B activated in response to *Lm*. The same cells were cultured for 24 h after stimulation, and NO or IL-6 were assayed in supernatants as described in Material and Methods. *C*, H22 cells with or without TLR2 and TLR4 siRNA were treated with heat-killed *Lm*, and the proliferation of cells was assayed as described in Materials and Methods. *D*, blockade of TLR2 signaling impaired *Lm*-mediated tumor promotion. BALB/c mice were inoculated by s.c. injection with 2×10^6 TLR2 or control siRNA-expressing H22 tumor cells. Fifteen days after inoculation, 1×10^6 CFU of *Lm* were injected directly into the local tumor of mice and tumor volumes were measured.

TLR2 of tumor cells promoted tumor growth by the activation of NF- κ B and MAPKs, leading to the acceleration of tumor cell proliferation and secretion of IL-6 and NO.

NF- κ B functions as a tumor promoter in inflammation-associated cancer (24, 25). The activation of NF- κ B is a critical mechanism leading to protection of tumor cells from apoptotic stress (6). NF- κ B also induces cell proliferation and augments angiogenesis by enhancing the expression of vascular endothelial growth factor (26). Although it is known that TLR-mediated signal transduction leads to the activation of NF- κ B (27, 28), the mechanism whereby NF- κ B is chronically activated in tumors still remains to be elucidated. We report that long-term activation of NF- κ B in tumors may be due to persistence of bacteria within the tumor. Significantly, knockdown of TLR2, but not TLR4, inhibited *Lm*-induced IL-6 and NO secretion as well as enhanced tumor proliferation. The promotion of tumor growth by bacteria has been reported to require the induction of host systemic or local immune suppression. Recombinant *Lm* and other bacteria have been reported (3, 12) to induce the generation of Treg in tumor-bearing hosts. However, in our tumor model, *Lm* had no effect on numbers of either Treg or MSCs within 10 days. We suggest that immunosuppression can be initiated rapidly by engagement of tumor TLRs, resulting in a cascade leading to tumor evasion from immune surveillance (14). NO and IL-6 produced by tumor cells, induced by lipopolysaccharide activation of the TLR4 signaling pathway, inhibits T-cell proliferation and NK cell activity (14). We found in this study that the production of NO and IL-6 was induced by *Lm* through TLR2 pathway, indicating that *Lm* stimulated the production of immunosuppressive molecules by tumor cells.

Genetically modified nonpathogenic bacteria have been used to deliver immune-activating or tumoricidal molecules for cancer therapy (29–31). Recent reports indicated that bacteria, such as *Salmonella* (32) and *Lm* (11, 33), can be used for tumor therapy, which requires high doses of bacteria, small initial tumor burden, and prevaccination with either recombinant bacterial vaccine or bacteria-loaded dendritic cells. However, in large tumors, we show that bacteria may persist after systemic bacterial clearance due to immunosuppressive cells and cytokines that may inhibit local immune cell-mediated bacterial killing. This immunosuppression may also partially explain why *Lm*-activated T cells cannot efficiently eliminate *Lm*-infected tumor cells *in vivo*.

In summary, our findings revealed a direct interaction between bacteria and tumor cells using a *Lm*-infected tumor model. Significantly, this phenomenon was also observed in clinical samples of *H. pylori*-associated gastric carcinoma. The infection-induced inflammation due to the activation of tumor cell NF- κ B is likely to be an important factor favoring tumor progression. However, attention should also be paid to the effects of the pathogens on the tumors because the signaling induced by the interaction between bacteria and tumor cell TLR results in the continuous activation of NF- κ B and MAPKs in tumor cells and thus drives proliferation directly.

Acknowledgments

Received 11/3/2006; revised 1/24/2007; accepted 2/28/2007.

Grant support: National Development Program (973) For Key Basic Research (2002CB513100) of China.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References

1. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. *Cell* 2006;124:823–35.
2. Lax AJ, Thomas W. How bacteria could cause cancer: one step at a time. *Trends Microbiol* 2002;10:293–9.
3. Rao VP, Poutahidis T, Ge Z, et al. Innate immune inflammatory response against enteric bacteria *Helicobacter hepaticus* induces mammary adenocarcinoma in mice. *Cancer Res* 2006;66:7395–400.
4. Takeda K, Kaisho T, Akira S. Toll like receptors. *Annu Rev Immuno* 2003;21:335–76.
5. Medzhitov R. Toll-like receptors and innate immunity. *Nat Rev Immuno* 2001;1:135–45.
6. Keller SA, Hernandez-Hopkins D, Vider J, et al. NF- κ B is essential for the progression of KSHV- and EBV-infected lymphomas *in vivo*. *Blood* 2006;107:3295–302.
7. Coussens LM, Werb Z. Inflammation and cancer. *Nature* 2002;420:860–7.
8. Punj V, Saint-Dic D, Daghfal S, Kanwar JR. Microbial-based therapy of cancer: a new twist to age old practice. *Cancer Biol Ther* 2004;3:708–14.
9. Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. *Lancet Oncol* 2003;4:548–56.
10. Pamer EG. Immune responses to *Listeria monocytogenes*. *Nat Rev Immuno* 2004;4:812–23.
11. Brockstedt DG, Giedlin MA, Leong ML, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. *Proc Natl Acad Sci U S A* 2004;101:13832–7.
12. Hussain SF, Paterson Y. What is needed for effective anti-tumor immunotherapy? Lessons learned using *Listeria monocytogenes* as a live vector for HPV-associated tumors. *Cancer Immunol Immunother* 2005; 54:577–86.
13. Starks H, Bruhn KW, Shen H, et al. *Listeria monocytogenes* as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. *J Immunol* 2004;173:420–7.
14. Huang B, Zhao J, Li HX, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. *Cancer Res* 2005;65:5009–14.
15. Zheng SJ, Jiang J, Shen H, Chen YH. Reduced apoptosis and ameliorated listeriosis in TRAIL-null mice. *J Immunol* 2004;173:5652–8.
16. Martin-Fontecha A, Thomsen LL, Brett S, et al. Induced recruitment of NK cells to lymph nodes provides IFN- γ for T(H)1 priming. *Nat Immunol* 2004;5:1260–5.
17. Ohya S, Tanabe Y, Makino M, et al. The contributions of reactive oxygen intermediates and reactive nitrogen intermediates to listericidal mechanisms differ in macrophages activated pre- and postinfection. *Infect Immun* 1998;66:4043–9.
18. Huang B, Pan PY, Li QS, et al. Gr-1⁺CD115⁺ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. *Cancer Res* 2006;66:1123–31.
19. Plevy SE, Gemberling JH, Hsu S, Dorner AJ, Smale ST. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. *Mol Cell Biol* 1997;17:4572–88.
20. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. *Curr Opin Immunol* 2004;16:157–62.
21. Beyer M, Schultze JL. Regulatory T cells in cancer. *Blood* 2006;108:804–11.
22. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. *Semin Cancer Biol* 2006;16:53–5.
23. Young MR, Lathers DM. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. *Int J Immunopharmacol* 1999;21: 241–52.
24. Pikarsky E, Porat RM, Stein I, et al. NF- κ B functions as a tumour promoter in inflammation-associated cancer. *Nature* 2004;431:461–6.
25. Ditsworth D, Zong WX. NF- κ B: key mediator of inflammation-associated cancer. *Cancer Biol Ther* 2004; 3:1214–6.
26. Karin M, Greten FR. NF- κ B: linking inflammation and immunity to cancer development and progression. *Nat Rev Immuno* 2005;5:749–59.
27. Akira S, Takeda K. Toll-like receptor signalling. *Nat Rev Immuno* 2004;4:499–511.
28. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF- κ B pathway. *Trends Immunol* 2005;26:469–76.
29. Bermudes D, Zheng LM, King IC. Live bacteria as anticancer agents and tumor-selective protein delivery vectors. *Curr Opin Drug Discov Devel* 2002;5:194–9.
30. Theys J, Barbe S, Landuyt W, et al. Tumor-specific gene delivery using genetically engineered bacteria. *Curr Gene Ther* 2003;3:207–21.
31. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. *J Pathol* 2006;208: 290–8.
32. Avogadri F, Martinoli C, Petrovska L, et al. Cancer immunotherapy based on killing of *Salmonella*-infected tumor cells. *Cancer Res* 2005;65:3920–7.
33. Sewell DA, Shahabi V, Gunn GR, Pan ZK, Dominiecki ME, Paterson Y. Recombinant *Listeria* vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. *Cancer Res* 2004;64:8821–5.